282 related articles for article (PubMed ID: 7632930)
1. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
Mackinnon S; Papadopoulos EB; Carabasi MH; Reich L; Collins NH; Boulad F; Castro-Malaspina H; Childs BH; Gillio AP; Kernan NA
Blood; 1995 Aug; 86(4):1261-8. PubMed ID: 7632930
[TBL] [Abstract][Full Text] [Related]
2. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
3. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
4. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?
Mackinnon S; Papadopoulos EB; Carabasi MH; Reich L; Collins NH; O'Reilly RJ
Bone Marrow Transplant; 1995 Apr; 15(4):591-4. PubMed ID: 7655386
[TBL] [Abstract][Full Text] [Related]
6. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
7. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Baurmann H; Nagel S; Binder T; Neubauer A; Siegert W; Huhn D
Blood; 1998 Nov; 92(10):3582-90. PubMed ID: 9808551
[TBL] [Abstract][Full Text] [Related]
9. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.
Drobyski WR; Keever CA; Roth MS; Koethe S; Hanson G; McFadden P; Gottschall JL; Ash RC; van Tuinen P; Horowitz MM
Blood; 1993 Oct; 82(8):2310-8. PubMed ID: 8400284
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
11. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
[TBL] [Abstract][Full Text] [Related]
12. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
Porter DL; Roth MS; McGarigle C; Ferrara JL; Antin JH
N Engl J Med; 1994 Jan; 330(2):100-6. PubMed ID: 8259165
[TBL] [Abstract][Full Text] [Related]
13. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
Kolb HJ; Schattenberg A; Goldman JM; Hertenstein B; Jacobsen N; Arcese W; Ljungman P; Ferrant A; Verdonck L; Niederwieser D; van Rhee F; Mittermueller J; de Witte T; Holler E; Ansari H;
Blood; 1995 Sep; 86(5):2041-50. PubMed ID: 7655033
[TBL] [Abstract][Full Text] [Related]
15. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
16. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
[TBL] [Abstract][Full Text] [Related]
17. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy.
Novitzky N; Rubinstein R; Hallett JM; du Toit CE; Thomas VL
Transplantation; 2000 Apr; 69(7):1358-63. PubMed ID: 10798754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
